Factor VIII formulations in high ionic strength media

Details Factor VIII formulations in high ionic strength media Factor VIII formulations in high ionic strength media

1994-12-27

1997-02-25

Jacobson, Dian C.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530383, 930100, 435 696, A61K 3836, A61K 3837, C07K 14745, C07K 14755

Patent

active

056058845

ABSTRACT:
Stable, highly purified Factor VIII protein formulations are provided in high ionic strength media which comprises: sodium chloride, potassium chloride or mixtures thereof; calcium chloride; and histidine as the buffering agent.

REFERENCES:
patent: Re32011 (1985-10-01), Zimmerman
patent: 4089944 (1978-05-01), Thomas
patent: 4562072 (1985-12-01), Heimburger et al.
patent: 4578218 (1986-03-01), Saundry et al.
patent: 4597966 (1986-07-01), Zolton et al.
patent: 4623717 (1986-11-01), Fernandes et al.
patent: 4758657 (1988-07-01), Farb
patent: 4877608 (1989-10-01), Lee et al.
Larsen et al. (1973) Arch Pharm Chemi. Sci. Ed. 1, 41-53.
Armour Pharmaceutical Corp. "Full Disclosure: Antihemophilic Factor (Human, Monoclate, Factor VIII:C, Heat-Treated".

Affiliated with

Also associated with

Rating

Factor VIII formulations in high ionic strength media does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Factor VIII formulations in high ionic strength media, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor VIII formulations in high ionic strength media will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1974045